OVERSEA CHINESE BANKING Corp Ltd Makes New $1.56 Million Investment in Bristol Myers Squibb Company $BMY

OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, HoldingsChannel reports. The fund purchased 27,062 shares of the biopharmaceutical company’s stock, valued at approximately $1,559,000.

Other large investors have also made changes to their positions in the company. E Fund Management Co. Ltd. purchased a new stake in Bristol Myers Squibb in the second quarter valued at $742,000. Somerville Kurt F purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $223,000. MSH Capital Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $359,000. Live Oak Investment Partners purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth about $458,000. Finally, Frazier Financial Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth about $51,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $67.06 on Friday. The stock has a market capitalization of $136.98 billion, a price-to-earnings ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a 50-day moving average of $60.55 and a 200 day moving average of $59.37.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BMY. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a report on Wednesday, August 5th. JPMorgan Chase & Co. boosted their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Piper Sandler started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.